Nivolumab vs Tamoxifen
Nivolumab vs Tamoxifen: Overview
This comparison examines the pharmacological differences between Nivolumab and Tamoxifen.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Tamoxifen: Selective estrogen receptor modulator (SERM).
Pharmacokinetics
Half-life: Nivolumab β 27 days; Tamoxifen β 5-7 days.
Chemical Properties
Molecular Formula: Tamoxifen β C26H29NO.
Molecular Weight: Tamoxifen β 371.5150 g/mol.
Type: Nivolumab β Antibody; Tamoxifen β Small molecule.